<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clofazimine (United States: Available via expanded access program and FDA investigational drug [IND] protocol only): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clofazimine (United States: Available via expanded access program and FDA investigational drug [IND] protocol only): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Clofazimine (United States: Available via expanded access program and FDA investigational drug [IND] protocol only): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_pediatric" data-topicid="109477" href="/d/html/109477.html" rel="external">see "Clofazimine (United States: Available via expanded access program and FDA investigational drug [IND] protocol only): Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="111060" href="/d/html/111060.html" rel="external">see "Clofazimine (United States: Available via expanded access program and FDA investigational drug [IND] protocol only): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F46446877"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F46443867"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0420b197-b787-454c-a4f7-ba1634c55399">Erythema nodosum leprosum</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erythema nodosum leprosum:</b>
<b>Oral:</b>100 mg 3 times daily for a maximum of 12 weeks; taper to 100 mg twice daily for 12 weeks, and then to 100 mg once daily for 12 to 24 weeks. May be used with concomitant prednisolone (≤1 mg/kg/day) (WHO 2012).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b5ed2e8-831a-48de-a8f1-385126e430e1">Leprosy, lepromatous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leprosy, lepromatous (multibacillary):</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">National Hansen Disease Program: 50 mg once daily, in combination with dapsone and rifampin, for 24 months (NHDP [HRSA 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">World Health Organization: 50 mg once daily and 300 mg once a month (directly observed), in combination with dapsone and rifampin, for 12 months (WHO 2012).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3c1ffc1-3b2c-44e1-abea-6af15373b052">Mycobacterial infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial (nontuberculous) (eg, <i>M. abscessus</i>) infection (off-label use): Oral: </b>100 to 200 mg once daily as part of an appropriate combination regimen (ATS/ERS/ESCMID/IDSA [Daley 2020]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a332cb4b-40bc-4f93-9a74-b665db48cb3b">Tuberculosis, drug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, drug-resistant (off-</b>
<b>label use): Oral: </b>100 mg once daily as part of an appropriate combination regimen (AST/CDC/ERS/IDSA [Nahid 2019]); some experts recommend up to 200 mg once daily (Schluger 2020).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990269"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987471"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Avoid in patients with hepatic impairment (Child-Pugh classes A, B, and C) unless benefit outweighs risk.</p></div>
<div class="block doe drugH1Div" id="F46443869"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F46443868"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="109477" href="/d/html/109477.html" rel="external">see "Clofazimine (United States: Available via expanded access program and FDA investigational drug [IND] protocol only): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Clofazimine is not commercially available in the United States. Refer to "Prescribing and Access Restrictions" for additional information.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b5ed2e8-831a-48de-a8f1-385126e430e1">Leprosy, lepromatous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leprosy, lepromatous (multibacillary):</b> Limited data available: <b>Note:</b> In the United States, it is strongly recommended to contact the National Hansen's Disease Program for management of leprosy in children (NHDP/HRSA 2018a). Use in combination with dapsone and rifampin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>National Hansen Disease Program dosing</i>: Children and Adolescents: Oral: 1 mg/kg/dose once daily for 24 months; maximum dose: 50 mg/dose (NHDP/HRSA 2018a). <b>Note:</b> Lowest available capsule size is 50 mg, and capsule should not be opened; doses of 2 mg/kg/dose every other day are acceptable if needed based on dosage form constraints (NHDP/HRSA 2018b).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>World Health Organization dosing </i>(WHO 2018):</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;10 years: Oral: 50 mg twice weekly <b>and</b> 100 mg once monthly for 12 months.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents &lt;15 years:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: Oral: 50 mg twice weekly <b>and</b> 100 mg once monthly for 12 months.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: Oral: 50 mg once every other day <b>and</b> 150 mg once monthly for 12 months.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥15 years: Oral: 50 mg once daily <b>and</b> 300 mg once monthly for 12 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3c1ffc1-3b2c-44e1-abea-6af15373b052">Mycobacterial infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial (nontuberculous) infection (eg, <i>Mycobacterium abscessus</i>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Odontogenic infection, osteomyelitis:</i> Very limited data available: Oral: Children 3 to 9 years: Oral: 1 mg/kg/dose once daily as part of an appropriate combination regimen. Dosing from a retrospective case series of 27 children who received clofazimine as part of combination therapy for treatment of jaw osteomyelitis due to <i>M. abscessus</i> after an outbreak at a dental office. Due to dosage form limitations (smallest available capsule is 50 mg, which cannot be opened), the dose was adjusted and administered 2 to 6 times per week to achieve an average dose of ~1 mg/kg/day (Adler-Shohet 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary infection in patients without cystic fibrosis: </i>Limited data available<i>: </i>Children and Adolescents: Oral: 3 to 5 mg/kg/dose once daily as part of an appropriate combination regimen; maximum dose: 100 mg/dose; doses up to 200 mg are recommended in adults (BTS [Haworth 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary infection in patients with cystic fibrosis:</i> Limited data available: Children and Adolescents: Oral: 1 to 2 mg/kg/dose once daily as part of an appropriate combination regimen; maximum dose: 100 mg/dose. Due to dosage form limitations (smallest available capsule is 50 mg, which cannot be opened), higher doses may be administered less frequently (3 to 7 days per week) to achieve an average dose of 1 to 2 mg/kg/day (Cameron 2021; CFF/ECFS [Floto 2016]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53bc9bf4-ed66-4900-b102-e4c801fc9f09">Tuberculosis, active; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, active (drug-resistant); treatment:</b> Limited data available: Children and Adolescents: Oral: 2 to 5 mg/kg/dose once daily as part of an appropriate combination regimen; maximum dose: 100 mg/dose (ATS/CDC/ERS/IDSA [Nahid 2019]; WHO 2020). <b>Note:</b> May administer higher dose every other day if needed based on dosage form constraints (WHO 2020).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51260768"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; adult information suggests that no dosing adjustment is necessary for mild to moderate impairment; caution should be used in severe impairment.</p></div>
<div class="block dohp drugH1Div" id="F51089950"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on recommendations in adults, avoid use in any degree of hepatic impairment unless benefits outweigh risks.</p></div>
<div class="block adr drugH1Div" id="F49165744"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin discoloration (75% to 100%; orange-pink to brownish-black), ichthyosis (8% to 28%), xeroderma (8% to 28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: GI adverse effects (40% to 50%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (1% to 5%), skin rash (1% to 5%), discoloration of sweat (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum glucose (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (&gt;1%), diarrhea (&gt;1%), fecal discoloration (&gt;1%), nausea (&gt;1%), vomiting (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine discoloration (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased erythrocyte sedimentation rate (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Burning sensation of eyes (&gt;1%), conjunctival discoloration (&gt;1%), corneal changes (pigmentation; &gt;1%), dry eye syndrome (&gt;1%), eye irritation (&gt;1%), eye pruritus (&gt;1%), vision loss (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Discoloration of sputum (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acneiform eruption, anemia, anorexia, cheilosis, constipation, cystitis, dizziness, drowsiness, edema, eosinophilia, erythroderma, fatigue, fever, gastroenteritis, gastrointestinal hemorrhage, headache, hepatitis, hepatomegaly, hypokalemia, increased serum albumin, increased serum aspartate aminotransferase, increased serum bilirubin, intestinal obstruction, jaundice, lymphadenopathy, maculopathy (bull’s eye retinopathy), neuralgia, ostealgia, pain (vascular), phototoxicity, prolonged QT Interval on ECG, splenic infarction, taste disorder, thromboembolism, torsades de pointes, weight loss</p></div>
<div class="block coi drugH1Div" id="F49366479"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to clofazimine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F46443856"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Cases of torsades de pointes (TdP) with QT prolongation have been reported in patients taking &gt; 100 mg/day or in combination with other QT prolonging drugs. If TdP or QT prolongation occurs, patient must remain under medical surveillance while monitoring ECGs and cardiac rhythm.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic effects: May cause photosensitivity (Legendre 2012). Use skin protection and avoid prolonged exposure to sunlight; do not use tanning equipment. May cause skin dryness, pruritus, and ichthyosis; oil-based skin preparations may relieve symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: May accumulate as crystals in organs including intestinal mucosa, spleen and liver. Intestinal mucosa deposition may lead to obstruction that may require exploratory laparotomies in some patients. Splenic infarction and GI bleeding (some fatal) have also been reported. May be dose related; dosages &gt;100 mg/day should be used for the shortest duration possible (&lt;3 months) and only under close supervision. If patient complains of abdominal pain (colicky or burning), nausea, vomiting, or diarrhea, initiate clinical investigations and decrease dose, increase dosing interval, or discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin and body fluid discoloration: Discoloration of the skin (red to brownish-black) or conjunctivae, lacrimal fluid, sweat, sputum, urine and feces may occur in 75% to 100% of patients. Skin discoloration is reversible after treatment discontinuation; however, disappearance of discoloration may take several months to years.</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: Suicide has been reported (rare); thought to be related to depression due to skin discoloration. Advise patients about potential for skin discoloration and monitor for suicidal ideation during therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Use with caution in patients with a history of depression; skin discoloration caused by clofazimine may result in depression. Advise patients about potential for skin discoloration and monitor for depressive symptoms during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Use with caution in patients with gastrointestinal disorders, including abdominal pain and diarrhea.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lenses: Remove contact lenses during therapy; staining may occur (Legendre 2012).</p></div>
<div class="block foc drugH1Div" id="F22785794"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule, Oral: 50 mg</p></div>
<div class="block accres drugH1Div" id="F46443770"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Clofazimine is not commercially available in the United States. For the treatment of leprosy, information on how to access clofazimine is available from the National Hansen’s Disease Program (<a href="/external-redirect?target_url=https%3A%2F%2Fwww.hrsa.gov%2Fhansens-disease&amp;token=u%2FUXY8mj4f2cUyB56IXs7tlD1RWOM8j01WBiHfIam7B0OGIJQkB1L6M53xdyeR71&amp;TOPIC_ID=107872" target="_blank">https://www.hrsa.gov/hansens-disease</a>).</p>
<p style="text-indent:0em;margin-top:2em;">For the treatment of other nontuberculous mycobacterial (NTM) infections in adults contact the Novartis NTM program at 1-888-NOW-NOVA (1-888-669-6682). Eligibility criteria for the Novartis NTM program can be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT04334070&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSxlduZeD2EkUlT%2BK9CPcXgr7LYt2UK1%2BqV2zVcP2Bmn5w%3D%3D&amp;TOPIC_ID=107872" target="_blank">https://www.clinicaltrials.gov/study/NCT04334070</a>. For patients not eligible for the Novartis expanded access program providers should contact the Food and Drug Administration (FDA) Division of Anti-Infective products at 301-796-1400 or visit <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fabout-fda%2Fcenter-drug-evaluation-and-research-cder%2Fexpanded-access-clofazimine&amp;token=M8u0WbVDp5LJYjjLZ4FPALtsJ%2FESVvBjNHUm6qy%2Bvw8Fo9PNSrsJNs95%2BJrWuALdJOyYhRRsFAb5%2BzgZcoBTOBpOIbz90mZtvWo96mi3%2BwmRILTlk2%2BUpVe%2Bi%2BSLuz3e&amp;TOPIC_ID=107872" target="_blank">https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/expanded-access-clofazimine</a> for information on single patient IND requests.</p>
<p style="text-indent:0em;margin-top:2em;">International: No longer available commercially. In nations where a national leprosy elimination program exists, the Ministries of Health make an official request to the World Health Organization (WHO) for clofazimine. In nations where no such program exists, doctors or pharmacists from individual institutions contact the WHO with a request. A request can be made to the WHO via a letter, fax, or email to verify that the drug will be used to treat a severe ENL reaction due to leprosy and how many patients need the drug. If these conditions are met, a free supply of clofazimine will then be made available. For treatment of MDR-TB, the WHO handles decisions regarding distribution on an individual case-by-case basis. For additional information: http://www.who.int/lep/mdt/clofazimine/en/.</p></div>
<div class="block adm drugH1Div" id="F46443873"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with meals; capsules must be swallowed whole and should not be opened.</p></div>
<div class="block admp drugH1Div" id="F52612438"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with meals; capsules must be swallowed whole and should not be opened.</p></div>
<div class="block use drugH1Div" id="F46443774"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Leprosy:</b> Treatment of lepromatous (multibacillary) leprosy, in combination with other agents; treatment of erythema nodosum leprosum.</p></div>
<div class="block off-label drugH1Div" id="F54864952"><span class="drugH1">Use: Off-Label: Adult</span><p>Mycobacterial (nontuberculous, rapidly growing) infection; Tuberculosis, drug-resistant</p></div>
<div class="block mst drugH1Div" id="F46440424"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Clofazimine may be confused with cloZAPine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F46283930"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F46283927"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Substrates (High risk with Inhibitors): Clofazimine may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: Clofazimine may enhance the QTc-prolonging effect of Dabrafenib. Clofazimine may increase the serum concentration of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: Clofazimine may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Clofazimine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of Clofazimine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54896831"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in females of reproductive potential. Females of reproductive potential should use effective contraception during treatment for multidrug-resistant tuberculosis (Esmail 2018); the manufacturer recommends use of effective contraception during therapy and for ≥4 months after the last clofazimine dose.</p></div>
<div class="block pri drugH1Div" id="F46443943"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Clofazimine crosses the placenta (Freerksen 1992; Holdiness 1989).</p>
<p style="text-indent:0em;margin-top:2em;">Infants born to women who have received clofazimine during pregnancy had deeply pigmented skin at birth with gradual fading over 1 year (Holdiness 1989).</p>
<p style="text-indent:0em;margin-top:2em;">Clofazimine is approved for the treatment of leprosy. Leprosy may be exacerbated during pregnancy. Untreated disease may cause permanent damage to the maternal skin, nerves, limbs, and eyes (Ozturk 2017). The risk of erythema nodosum leprosum is increased during pregnancy when the cell-mediated immune system is depressed. Clofazimine is recommended for the treatment of lepromatous (multibacillary) leprosy during pregnancy (HRSA 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Clofazimine is used off label for the treatment of drug resistant tuberculosis. Tuberculosis (TB) disease (active TB) is associated with adverse fetal outcomes including intrauterine growth restriction, low birth weight, preterm birth, and perinatal death (Esmail 2018; Miele 2020) as well as adverse maternal outcomes, including increased risks for anemia and cesarean delivery. Placental transmission may rarely occur with active maternal disease (Miele 2020). Data are limited for use of second-line drugs in pregnancy (ie, clofazimine). Individualized regimens should be utilized to treat multidrug-resistant tuberculosis in pregnant patients; evidence to support a specific regimen is not available (ATS/CDC/ERS/IDSA [Nahid 2019]; WHO 2020).</p></div>
<div class="block brc drugH1Div" id="F46443855"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine is present in breast milk (Venkatesan 1997).</p>
<p style="text-indent:-2em;margin-left:2em;">Breast milk discoloration (red tint) has been reported (Freerksen 1992). Skin discoloration has also been noted in breastfed infants exposed to clofazimine through breast milk, with gradual fading after breastfeeding is stopped (Holdiness 1989; Ozturk 2017). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F46443875"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">GI symptoms (eg, abdominal pain, nausea, vomiting, diarrhea); skin for discoloration; periodically monitor liver function tests and serum creatinine (WHO 1998); pregnancy test prior to treatment (women of reproductive potential); ECG (with concomitant use of clofazimine and bedaquiline); depression or suicidal ideation</p></div>
<div class="block pha drugH1Div" id="F46443860"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Exact mechanism unknown; antibacterial activity may be due to binding to DNA of <i>Mycobacterium leprae</i>.</p></div>
<div class="block phk drugH1Div" id="F46443862"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Variable and incomplete (45% to 62%); may be increased when administered with food (Legendre 2012)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Highly lipophilic; deposits primarily in fatty tissues and cells of reticuloendothelial system</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~25 days (range: 6.5 to 160 days)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22786938"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lampren</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lampren</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lamperene</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Lampren</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Clofozine | Fazim | Hansepran | Lepromine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lampren</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lapren</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Fazim | Lamprene</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lampren</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Clofazimina Labesfal | Lamprene</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Lamcoin | Lamprene</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Clofazam | Lamprene</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Lampren</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Lamprene</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31310313">
<a name="31310313"></a>Adler-Shohet FC, Singh J, Nieves D, et al. Safety and tolerability of clofazimine in a cohort of children with odontogenic mycobacterium abscessus infection. <i>J Pediatric Infect Dis Soc</i>. 2020;9(4):483-485. doi:10.1093/jpids/piz049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/31310313/pubmed" id="31310313" target="_blank">31310313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34479810">
<a name="34479810"></a>Cameron LH, Peloquin CA, Hiatt P, et al. Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis. <i>J Cyst Fibros</i>. Published online August 31, 2021. doi:10.1016/j.jcf.2021.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/34479810/pubmed" id="34479810" target="_blank">34479810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32797222">
<a name="32797222"></a>Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.<i> Clin Infect Dis.</i> 2020;71(4):905-913. doi:10.1093/cid/ciaa1125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/32797222/pubmed" id="32797222" target="_blank">32797222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29997980">
<a name="29997980"></a>Esmail A, Sabur NF, Okpechi I, Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. <i>J Thorac Dis</i>. 2018;10(5):3102-3118. doi:10.21037/jtd.2018.05.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/29997980/pubmed" id="29997980" target="_blank">29997980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26666259">
<a name="26666259"></a>Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i>. 2016;71 Suppl 1(Suppl 1):i1-i22. doi:10.1136/thoraxjnl-2015-207360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/26666259/pubmed" id="26666259" target="_blank">26666259</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Freerksen E, Seydel JK. Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine. <i>Arzneimittelforschung</i>. 1992;42(10):1243-1245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/1472145/pubmed" id="1472145" target="_blank">1472145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29054853">
<a name="29054853"></a>Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). <i>Thorax</i>. 2017;72(Suppl 2):ii1-ii64. doi:10.1136/thoraxjnl-2017-210927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/29054853/pubmed" id="29054853" target="_blank">29054853</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Health Resources and Services Administration (HRSA). National Hansen's Disease (Leprosy) Program: Recommended Treatment Regimens. http://www.hansensdisease/diagnosis/recommendedtreatment.html. Accessed on July 13, 2020.</div>
</li>
<li>
<div class="reference">
                  Health Resources and Services Administration (HRSA), National Hansen's Disease Programs (NHDP). NHDP guide to the management of Hansen's disease. 2018a. <a href="https://www.hrsa.gov/sites/default/files/hrsa/hansens-disease/hansens-disease-guide-management.pdf" target="_blank">https://www.hrsa.gov/sites/default/files/hrsa/hansens-disease/hansens-disease-guide-management.pdf</a>. Accessed September 14, 2021.</div>
</li>
<li>
<div class="reference">
                  Health Resources and Services Administration (HRSA), National Hansen's Disease Programs (NHDP). Recommended treatment regimens. 2018b. <a href="https://www.hrsa.gov/hansens-disease/diagnosis/recommended-treatment.html" target="_blank">https://www.hrsa.gov/hansens-disease/diagnosis/recommended-treatment.html</a>. Accessed September 14, 2021.</div>
</li>
<li>
<div class="reference">
                  Holdiness MR. Clinical pharmacokinetics of clofazimine. A review. <i>Clin Pharmacokinet</i>. 1989;16(2):74-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/2656045/pubmed" id="2656045" target="_blank">2656045</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lamprene (clofazimine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; January 2019.</div>
</li>
<li>
<div class="reference">
                  Legendre DP, Muzny CA, Swiatlo E. Hansen's disease (Leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions. <i>Pharmacotherapy</i>. 2012;32(1):27-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/22392826/pubmed" id="22392826" target="_blank">22392826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32459437">
<a name="32459437"></a>Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):1444-1453. doi:10.1097/AOG.0000000000003890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/32459437/pubmed" id="32459437" target="_blank">32459437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31729908">
<a name="31729908"></a>Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. <i>Am J Respir Crit Care Med</i>. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/31729908/pubmed" id="31729908" target="_blank">31729908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27549245">
<a name="27549245"></a>Ozturk Z, Tatliparmak A. Leprosy treatment during pregnancy and breastfeeding: a case report and brief review of literature. <i>Dermatol Ther</i>. 2017;30(1). doi:10.1111/dth.12414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/27549245/pubmed" id="27549245" target="_blank">27549245</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Schluger NW, Heysell SK, Friedland G. Treatment of drug-resistant pulmonary tuberculosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 18, 2020.</div>
</li>
<li>
<div class="reference">
                  Szeto W, Garcia-Buitrago MT, Abbo L, Rosenblatt JD, Moshiree B, Morris MI. Clofazimine enteropathy: a rare and underrecognized complication of mycobacterial therapy. <i>Open Forum Infect Dis</i>. 2016;3(3):ofw004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/27800519/pubmed" id="27800519" target="_blank">27800519</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration (FDA). FDA Drug Safety Communication. MedWatch. Lamprene (Clofazimine). <a href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm514749.htm" target="_blank">http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm514749.htm</a>. Accessed November 11, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9364825">
<a name="9364825"></a>Venkatesan K, Mathur A, Girdhar A, Girdhar BK. Excretion of clofazimine in human milk in leprosy patients. <i>Lepr Rev</i>. 1997;68(3):242-6. doi:10.5935/0305-7518.19970033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/9364825/pubmed" id="9364825" target="_blank">9364825</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). <i>Drugs Used in Leprosy.</i>
                     http://apps.who.int/medicinedocs/pdf/h2988e/h2988e.pdf. Accessed April 6, 2016.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Guidelines for the diagnosis, treatment and prevention of leprosy. 2018. https://apps.who.int/iris/handle/10665/274127. Accessed September 14, 2021.</div>
</li>
<li>
<div class="reference">
                  World Health Organization. WHO Expert Committee on Leprosy. <i>World Health Organ Tech Rep Ser</i>. 2012;(968):1-61, 1 p following 61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofazimine-united-states-available-via-expanded-access-program-and-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/22970604/pubmed" id="22970604" target="_blank">22970604</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). WHO model prescribing information: drugs used in leprosy. 1998. https://apps.who.int/iris/handle/10665/64636. Accessed September 14, 2021.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. https://www.who.int/publications/i/item/9789240007048. Published 2020. Accessed July 13, 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 107872 Version 77.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
